Sugi Predict

Sugi Predict / Compounds / SCHEMBL392360

SCHEMBL392360

SCHEMBL392360

COc1ccc(CN2CCNCC2)c(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.62
▸ CHRM2 P08172 1/20 0.62
▸ SLC6A4 P31645 1/20 0.62
▸ OPRD1 P41143 1/20 0.62
▸ OPRK1 P41145 1/20 0.62
▸ APOBEC3A P31941 1/20 0.61
▸ CTDSP1 Q9GZU7 1/20 0.61
▸ APOBEC3G Q9HC16 1/20 0.61
▸ KDM4E B2RXH2 6/20 0.60
▸ MAPK1 P28482 1/20 0.60
▸ ALDH1A1 P00352 4/20 0.57
▸ MAPT P10636 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ TDP1 Q9NUW8 2/20 0.57
▸ GAA P10253 1/20 0.57
▸ MEN1 O00255 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ POLB P06746 3/20 0.55
▸ MELK Q14680 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7300721 0.88 CYP1A2 (0.62) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL9831262 0.86 KDM4E (0.64) KDM4EMAPK1ALDH1A1MAPTLMNA
SCHEMBL22542166 0.85 CYP1A2 (0.62) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL17696097 0.85 HTR3E (0.57) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL28191688 0.84 KDM4E (0.63) KDM4EMAPK1ALDH1A1MAPTLMNA
SCHEMBL17009558 0.84 CYP1A2 (0.54) CYP1A2CHRM2SLC6A4OPRD1OPRK1
SCHEMBL25988241 0.83 KDM4E (0.61) KDM4EMAPK1ALDH1A1MAPTLMNA
SCHEMBL9804694 0.82 KDM4E (0.61) KDM4EMAPK1ALDH1A1MAPTLMNA
SCHEMBL21587706 0.82 KDM4E (0.64) KDM4EMAPK1ALDH1A1MAPTLMNA
SCHEMBL22460434 0.81 APLNR (0.56) SLC6A4KDM4EMAPK1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-10654855-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2020-05-19 — — US disclosed
US-20180312516-A1 Protein Kinase B Inhibitors ASTRAZENECA AB (SE) 2018-11-01 — — US disclosed
US-10059714-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2018-08-28 — — US disclosed
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2017-03-02 — — US disclosed
US-9492453-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2016-11-15 — — US disclosed
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2015-07-02 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
EP-2201012-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS AstraZeneca AB (SE) 2010-06-30 — — EP disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed
US-5965560-A AS DOPAMINE ANTAGONISTS AND ANTIPSYCHOTIC AGENTS WARNER-LAMBERT COMPANY (US) 1999-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CHRM2 2059/4885SLC6A4 4654/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CHRM2 2059/4885SLC6A4 4654/4885
US-20180312516-A1 Protein Kinase B Inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CHRM2 2059/4885SLC6A4 4654/4885
US-10654855-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CHRM2 2059/4885SLC6A4 4654/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CHRM2 2059/4885SLC6A4 4654/4885
US-10059714-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CHRM2 2059/4885SLC6A4 4654/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP1A2 3895/4885CHRM2 1949/4885SLC6A4 4739/4885
US-20170057969-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP1A2 3895/4885CHRM2 1949/4885SLC6A4 4739/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CHRM2 2059/4885SLC6A4 4654/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP1A2 3895/4885CHRM2 1949/4885SLC6A4 4739/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CHRM2 2059/4885SLC6A4 4654/4885
US-20150182531-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 CYP1A2 3895/4885CHRM2 1949/4885SLC6A4 4739/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 CYP1A2 3544/4885CHRM2 2059/4885SLC6A4 4654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.